Skip to content

IGC Pharma, Inc.

IGC

CIK 0001326205

← back to feed
Revenue (TTM)
$1.17M
−31.6% YoY Q1 Apr 2026
Net Income (TTM)
−$7.02M
+41.8% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.08
+44.4% YoY Q1 Apr 2026
Gross Margin
39.6%
Q1 Apr 2026
Operating Margin
-744.0%
Q1 Apr 2026
Net Margin
-602.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$5.18M
Q1 Apr 2026
Cash
$207K
Q1 Apr 2026
Total Debt
$134K
Q1 Apr 2026
Shares Outstanding
100.09M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings